Nishimura H, Yamada T, Hagio Y, Inoue T, Tsunawaki A, Yakushiji M, Kato T
Gan To Kagaku Ryoho. 1983 Apr;10(4 Pt 1):938-43.
Twenty-five patients with advanced ovarian cancer were treated with Cis-dichlorodiammneplatinum (CD-DP) 50 mg/m2 as single agent or CDDP 50 mg/m2 in combination with adriamycin (ADM) 50 mg/m2. Both CDDP and CDDP-ADM combination were administered intravenously. Thirteen patients received CDDP alone and twelve patients received CDDP-ADM combination. The single agent activity of CDDP produced a complete response (CR) of 23.1% and a partial response of 15.4% with an overall response rate of 38.5%. The combination of CDDP and ADM gave a response of 58.3% (CR 25.0%, PR 33.3%). Thus, the combination of CDDP and ADM produced a response rate superior to that of CDDP alone. These clinical findings were supported by our investigation of novel experimental therapies in 7, 12 dimethylbenz (a) anthracene induced rat ovarian cancer.
25例晚期卵巢癌患者接受顺二氯二氨铂（CD-DP）单药治疗，剂量为50mg/m²，或接受顺铂50mg/m²联合阿霉素（ADM）50mg/m²治疗。顺铂及顺铂-阿霉素联合用药均通过静脉给药。13例患者接受顺铂单药治疗，12例患者接受顺铂-阿霉素联合治疗。顺铂单药治疗的有效率为23.1%，部分缓解率为15.4%，总有效率为38.5%。顺铂与阿霉素联合治疗的有效率为58.3%（完全缓解率25.0%，部分缓解率33.3%）。因此，顺铂与阿霉素联合治疗的有效率高于顺铂单药治疗。我们对7,12-二甲基苯并(a)蒽诱导的大鼠卵巢癌进行的新型实验性治疗研究支持了这些临床发现。
